Markets

Puma Biotechnology Initiates Phase 2 ALISCA-Lung2 Trial Of Alisertib In Advanced Small Cell Lung Cancer

Sep 17, 2026 · 04:10 PM ET· updated 1h ago

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with

Why It Matters

Puma started testing a cancer medicine called alisertib on patients with advanced lung cancer. When a drug company moves forward with new patient tests, it means they believe the medicine might work and help people.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

PBYI9.54

+0.14 (+1.54%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.